149 related articles for article (PubMed ID: 2044648)
41. Clinical trials including an update on the Helsinki Heart Study.
Brown WV
Am J Cardiol; 1990 Sep; 66(6):11A-15A. PubMed ID: 2203244
[TBL] [Abstract][Full Text] [Related]
42. Reduction in coronary heart disease: clinical and anatomical considerations.
Satler LF; Pearle DL; Rackley CE
Clin Cardiol; 1989 Aug; 12(8):422-6. PubMed ID: 2670383
[TBL] [Abstract][Full Text] [Related]
43. [China coronary secondary prevention study (CCSPS)].
Lu ZL;
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb; 33(2):109-15. PubMed ID: 15924803
[TBL] [Abstract][Full Text] [Related]
44. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
[TBL] [Abstract][Full Text] [Related]
45. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).
Kjekshus J; Pedersen TR
Am J Cardiol; 1995 Sep; 76(9):64C-68C. PubMed ID: 7572690
[TBL] [Abstract][Full Text] [Related]
46. Commentary on the published results of the Lipid Research Clinics Coronary Primary Prevention Trial.
Kronmal RA
JAMA; 1985 Apr; 253(14):2091-3. PubMed ID: 3883022
[No Abstract] [Full Text] [Related]
47. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
[TBL] [Abstract][Full Text] [Related]
48. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
49. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
[TBL] [Abstract][Full Text] [Related]
50. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
[TBL] [Abstract][Full Text] [Related]
51. Long-term follow-up of the West of Scotland Coronary Prevention Study.
Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
[TBL] [Abstract][Full Text] [Related]
52. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
Goldbourt U; Behar S; Reicher-Reiss H; Agmon J; Kaplinsky E; Graff E; Kishon Y; Caspi A; Weisbort J; Mandelzweig L
Am J Cardiol; 1993 Apr; 71(11):909-15. PubMed ID: 8465780
[TBL] [Abstract][Full Text] [Related]
53. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study.
Am J Cardiol; 1995 Sep; 76(7):485-91. PubMed ID: 7653449
[TBL] [Abstract][Full Text] [Related]
54. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.
Sprecher DL; Abrams J; Allen JW; Keane WF; Chrysant SG; Ginsberg H; Fischer JJ; Johnson BF; Theroux P; Jokubaitis L
Ann Intern Med; 1994 Apr; 120(7):537-43. PubMed ID: 8093139
[TBL] [Abstract][Full Text] [Related]
55. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
56. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.
Richter WO; Donner MG; Höfling B; Schwandt P
Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236
[TBL] [Abstract][Full Text] [Related]
57. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
[TBL] [Abstract][Full Text] [Related]
58. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment.
Riegger G; Abletshauser C; Ludwig M; Schwandt P; Widimsky J; Weidinger G; Welzel D
Atherosclerosis; 1999 May; 144(1):263-70. PubMed ID: 10381299
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
